MCID: BRS049
MIFTS: 51

Breast Carcinoma in Situ malady

Categories: Cancer diseases, Genetic diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Breast Carcinoma in Situ

Aliases & Descriptions for Breast Carcinoma in Situ:

Name: Breast Carcinoma in Situ 12 14
Non-Infiltrating Carcinoma of Breast 12
Carcinoma in Situ of Breast 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8791
ICD10 33 D05 D05.9
ICD9CM 35 233.0
NCIt 47 C3641
SNOMED-CT 64 154636004 189336000
UMLS 69 C0154084

Summaries for Breast Carcinoma in Situ

MalaCards based summary : Breast Carcinoma in Situ, also known as non-infiltrating carcinoma of breast, is related to lobular neoplasia and comedo carcinoma. An important gene associated with Breast Carcinoma in Situ is ERBB2 (Erb-B2 Receptor Tyrosine Kinase 2), and among its related pathways/superpathways are Signaling by GPCR and Apoptotic Pathways in Synovial Fibroblasts. The drugs Doxorubicin and Progesterone have been mentioned in the context of this disorder. Affiliated tissues include breast and testes, and related phenotypes are Decreased viability and cardiovascular system

Related Diseases for Breast Carcinoma in Situ

Diseases in the Breast Cancer family:

Breast Benign Neoplasm Inflammatory Breast Carcinoma
Sporadic Breast Cancer Breast Carcinoma in Situ
Familial Breast Cancer Bard1-Related Susceptibility to Breast Cancer
Brip1-Related Breast Cancer Chek2-Related Susceptibility to Breast Cancer
Rad51-Related Susceptibility to Breast Cancer

Diseases related to Breast Carcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 159)
id Related Disease Score Top Affiliating Genes
1 lobular neoplasia 11.4
2 comedo carcinoma 11.1
3 breast apocrine carcinoma in situ 11.1
4 aorto-ventricular tunnel 10.4 BRCA1 BRCA2
5 kunjin encephalitis 10.3 BRCA1 BRCA2 ERBB2
6 nemaline myopathy 8, autosomal recessive 10.3 BRCA1 BRCA2 ERBB2
7 mediastinum synovial sarcoma 10.3 BRCA1 BRCA2 TP53
8 cellular ependymoma 10.3 BRCA1 BRCA2 TP53
9 mycobacterium kansasii 10.3 BRCA1 BRCA2 TP53
10 burn scar 10.3 BRCA1 BRCA2
11 nasal cavity adenocarcinoma 10.3 BRCA2 ERBB2 FGFR1
12 larynx liposarcoma 10.2 BRCA1 BRCA2 TP53
13 lung clear cell-sugar-tumor 10.2 BRCA1 BRCA2 ERBB2 TP53
14 bladder colloid adenocarcinoma 10.2 BRCA1 BRCA2 ERBB2 TP53
15 lethal congenital contracture syndrome 7 10.2 BRCA1 BRCA2
16 renal adenoma 10.2 FLT4 VEGFA VEGFC
17 marginal zone b-cell lymphoma 10.2 MMP2 TP53 VEGFA
18 lower lip cancer 10.2 ERBB2 MET MMP2
19 maxillary sinus cholesteatoma 10.2 MMP2 TP53 VEGFC
20 pulmonary fibrosis and/or bone marrow failure, telomere-related, 1 10.2 ERBB2 MMP2 TP53 VEGFA
21 traumatic brain injury 10.2 MMP2 TP53 VEGFC
22 bladder clear cell adenocarcinoma 10.2 ESR1 TP53
23 vesiculobullous skin disease 10.2 FLT4 KDR VEGFA
24 multinodular goiter 10.2 ERBB2 KDR VEGFA
25 factitious disorder 10.2 FLT4 KDR VEGFA
26 bipolar i disorder 10.2 FGF2 IL6 VEGFA
27 glucose-6-phosphate translocase deficiency 10.1 ERBB2 MET TP53 VEGFA
28 mouth disease 10.1 ERBB2 PGR
29 gestational choriocarcinoma 10.1 FGF2 TP53 VEGFA
30 lattice corneal dystrophy 10.1 ERBB2 FGF2 MMP2 TP53
31 urinary bladder posterior wall cancer 10.1 FGF2 IL6 VEGFA
32 benign idiopathic neonatal seizures 10.1 FGF2 KDR VEGFA
33 pediatric germ cell cancer 10.1 MET MMP2 VEGFA VEGFC
34 aortitis 10.1 PGR TP53
35 spinocerebellar ataxia 25 10.1 IL6 KDR VEGFA
36 vulvitis 10.1 IL6 KDR VEGFA
37 cleft palate cardiac defect ectrodactyly 10.1 KDR MET TP53 VEGFA
38 fallopian tube adenocarcinoma 10.1 ERBB2 ESR1 TP53
39 subdural empyema 10.1 FGF2 KDR VEGFA
40 human granulocytic anaplasmosis 10.1 FLT4 KDR TP53 VEGFA
41 autoimmune disease of cardiovascular system 10.1 BRCA1 BRCA2 PGR
42 heart malignant hemangiopericytoma 10.1 BRCA1 BRCA2 PGR
43 anterograde amnesia 10.1 FGF2 IL6 VEGFA
44 benign familial neonatal epilepsy 10.1 FLT4 KDR VEGFA VEGFC
45 ductal carcinoma in situ 10.0
46 plague 10.0 ERBB2 ESR1 TP53
47 reactive arthritis 10.0 ERBB2 PGR TP53
48 tumor of exocrine pancreas 10.0 ESR1 FGF2 VEGFA
49 pneumonia 10.0 BRCA1 BRCA2 PGR
50 glycogen storage disease 10.0 ERBB2 MET TP53 VEGFA VEGFC

Graphical network of the top 20 diseases related to Breast Carcinoma in Situ:



Diseases related to Breast Carcinoma in Situ

Symptoms & Phenotypes for Breast Carcinoma in Situ

GenomeRNAi Phenotypes related to Breast Carcinoma in Situ according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 9.53 ESR1 FGFR1 KDR
2 Decreased viability GR00221-A-2 9.53 BRCA1 ESR1 FGFR1 FLT4 KDR
3 Decreased viability GR00221-A-3 9.53 BRCA1 KDR
4 Decreased viability GR00221-A-4 9.53 ESR1 KDR
5 Decreased viability GR00301-A 9.53 BRCA1
6 Decreased viability GR00342-S-1 9.53 FLT4
7 Decreased viability GR00342-S-2 9.53 FLT4
8 Decreased viability GR00342-S-3 9.53 FLT4
9 Decreased substrate adherent cell growth GR00193-A-1 9.35 MET
10 Decreased substrate adherent cell growth GR00193-A-3 9.35 MET
11 Decreased substrate adherent cell growth GR00193-A-4 9.35 KDR MET FGFR1

MGI Mouse Phenotypes related to Breast Carcinoma in Situ:

44 (show all 25)
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.54 BRCA1 ERBB2 ESR1 FGF2 FGFR1 FLT4
2 homeostasis/metabolism MP:0005376 10.49 PGR TP53 VEGFA VEGFC BRCA1 BRCA2
3 cellular MP:0005384 10.48 KRT19 LIF MET PGR TP53 VEGFA
4 behavior/neurological MP:0005386 10.46 BRCA1 BRCA2 ERBB2 ESR1 FGF2 FGFR1
5 growth/size/body region MP:0005378 10.45 MMP2 TP53 VEGFA BRCA1 BRCA2 ERBB2
6 mortality/aging MP:0010768 10.45 ERBB2 ESR1 FGF2 FGFR1 FLT4 IL6
7 embryo MP:0005380 10.44 BRCA1 BRCA2 ERBB2 ESR1 FGFR1 FLT4
8 immune system MP:0005387 10.42 BRCA1 BRCA2 ESR1 FGFR1 FLT4 IL6
9 digestive/alimentary MP:0005381 10.41 BRCA1 BRCA2 ERBB2 ESR1 FGFR1 FLT4
10 endocrine/exocrine gland MP:0005379 10.4 BRCA1 BRCA2 ERBB2 ESR1 FGFR1 IL6
11 hematopoietic system MP:0005397 10.38 BRCA2 ESR1 FGF2 FGFR1 IL6 IL6ST
12 integument MP:0010771 10.38 BRCA1 BRCA2 ERBB2 ESR1 FGFR1 FLT4
13 muscle MP:0005369 10.32 BRCA1 ERBB2 ESR1 FGF2 FGFR1 FLT4
14 nervous system MP:0003631 10.31 KRT19 LIF MET MMP2 TP53 VEGFA
15 neoplasm MP:0002006 10.27 BRCA1 BRCA2 ERBB2 ESR1 FGF2 IL6
16 limbs/digits/tail MP:0005371 10.22 ESR1 FGFR1 IL6ST MET PGR TP53
17 normal MP:0002873 10.21 TP53 VEGFA BRCA1 BRCA2 ERBB2 ESR1
18 adipose tissue MP:0005375 10.17 BRCA1 ESR1 FLT4 IL6 IL6ST LIF
19 liver/biliary system MP:0005370 10.16 MET TP53 VEGFA ESR1 FLT4 IL6
20 reproductive system MP:0005389 10.1 BRCA1 BRCA2 ERBB2 ESR1 FGF2 FGFR1
21 no phenotypic analysis MP:0003012 10.06 ESR1 FGFR1 FLT4 KDR KRT19 MET
22 renal/urinary system MP:0005367 9.87 BRCA1 ESR1 FGFR1 IL6 MET TP53
23 respiratory system MP:0005388 9.85 BRCA1 ERBB2 ESR1 IL6 KDR LIF
24 skeleton MP:0005390 9.83 BRCA2 ERBB2 ESR1 FGF2 FGFR1 IL6
25 vision/eye MP:0005391 9.32 FGF2 FGFR1 IL6 IL6ST KDR LIF

Drugs & Therapeutics for Breast Carcinoma in Situ

Drugs for Breast Carcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 248)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
2
Progesterone Approved, Vet_approved Phase 3,Phase 2,Early Phase 1 57-83-0 5994
3
Estradiol Approved, Investigational, Vet_approved Phase 3,Phase 2 50-28-2 5757 53477783
4
Paclitaxel Approved, Vet_approved Phase 3,Phase 2 33069-62-4 36314
5
Tamoxifen Approved Phase 3,Phase 2,Phase 1 10540-29-1 2733526
6
Carboplatin Approved Phase 3,Phase 2 41575-94-4 10339178 498142 38904
7
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
8
Trastuzumab Approved, Investigational Phase 3,Phase 2,Phase 1 180288-69-1 9903
9
Fluorouracil Approved Phase 3,Phase 2 51-21-8 3385
10
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
11
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
12
Letrozole Approved, Investigational Phase 3,Phase 2,Phase 1 112809-51-5 3902
13
Anastrozole Approved, Investigational Phase 3,Phase 2 120511-73-1 2187
14
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
15
Norethindrone Approved Phase 3 68-22-4 6230
16
Medroxyprogesterone acetate Approved, Investigational Phase 3 71-58-9
17
Metformin Approved Phase 3,Early Phase 1 657-24-9 14219 4091
18
Exemestane Approved, Investigational Phase 3,Phase 2 107868-30-4 60198
19
Oxybutynin Approved, Investigational Phase 3 5633-20-5 4634
20
Pembrolizumab Approved Phase 3,Phase 2 1374853-91-4
21
Pertuzumab Approved Phase 3,Phase 1,Phase 2 145040-37-5, 380610-27-5 2540
22
leucovorin Approved, Nutraceutical Phase 3 58-05-9 54575, 6560146 143
23
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
24
Cholecalciferol Approved, Nutraceutical Phase 3,Phase 1,Phase 2 67-97-0 6221 10883523 5280795
25
Ergocalciferol Approved, Nutraceutical Phase 3,Phase 1,Phase 2 50-14-6 5280793
26
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
27
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
28
Lapatinib Approved March 2007, Investigational Phase 3,Phase 2,Phase 1 231277-92-2, 388082-78-8 208908 9941095
29 Estradiol valerate Phase 3,Phase 2 979-32-8
30 Alkylating Agents Phase 3,Phase 2
31 Selective Estrogen Receptor Modulators Phase 3,Phase 2,Phase 1
32 Steroid Synthesis Inhibitors Phase 3,Phase 2,Phase 1
33 Albumin-Bound Paclitaxel Phase 3,Phase 2
34 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
35 Hormone Antagonists Phase 3,Phase 2,Phase 1,Early Phase 1
36 Anesthetics Phase 3,Phase 2,Phase 1
37 Hormones Phase 3,Phase 2,Phase 1,Early Phase 1
38 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1,Early Phase 1
39 Estradiol 17 beta-cypionate Phase 3,Phase 2
40 Estradiol 3-benzoate Phase 3,Phase 2
41 Estrogen Antagonists Phase 3,Phase 2,Phase 1
42 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
43 Estrogen Receptor Modulators Phase 3,Phase 2,Phase 1
44 Estrogens Phase 3,Phase 2,Phase 1
45 Polyestradiol phosphate Phase 3,Phase 2
46 Immunosuppressive Agents Phase 3,Phase 2
47 Antimetabolites Phase 3,Phase 2,Phase 1
48 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
49 Antimetabolites, Antineoplastic Phase 3,Phase 2
50 Antimitotic Agents Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 311)
id Name Status NCT ID Phase
1 Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml® Completed NCT01448447 Phase 4
2 Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer Completed NCT00742222 Phase 4
3 Breast-Conserving Surgery and Whole-Breast Radiation Therapy With or Without Additional Radiation Therapy to the Tumor in Treating Women With Ductal Carcinoma in Situ Unknown status NCT00907868 Phase 3
4 Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy Completed NCT00053898 Phase 3
5 Genetic Counseling or Usual Care in Helping Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I, Stage II, or Stage IIIA Breast Cancer Make Treatment Decisions Completed NCT00262899 Phase 3
6 Evaluation of the Diagnostic Performance of MRI±Biopsy to Optimize Resection of Ductal Carcinoma In Situ (DCIS) Breast Cancer Completed NCT01112254 Phase 3
7 Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ Completed NCT00438659 Phase 3
8 S9630, Medroxyprogesterone in Treating Women With Breast Cancer Completed NCT00002920 Phase 3
9 Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer Completed NCT00026286 Phase 3
10 Hormone Replacement Therapy and the Risk of Breast Cancer Recurrence in Women With Previous Early Stage Breast Cancer Completed NCT00003771 Phase 3
11 Intraoperative Gamma Camera for Breast Cancer Surgery Completed NCT00757302 Phase 3
12 Study of Docetaxel in Breast Cancer Patients Completed NCT00174707 Phase 3
13 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
14 "The Efficacy of 'Radioguided Occult Lesion Localization' (ROLL) Versus 'Wire-guided Localization' (WGL) in Breast Conserving Surgery for Non-palpable Breast Cancer: a Randomized Clinical Trial" Completed NCT00539474 Phase 3
15 Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer Completed NCT00021255 Phase 3
16 Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women Completed NCT00003906 Phase 3
17 Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer Completed NCT00075270 Phase 3
18 Chemotherapy or Letrozole Before Surgery in Treating Postmenopausal Women With Breast Cancer That Can Be Removed By Surgery Completed NCT00963729 Phase 3
19 Metformin Hydrochloride in Patients With Atypical Hyperplasia or In Situ Breast Cancer to Placebo in Decreasing Atypical Cells in Patients With Atypical Hyperplasia or in Situ Breast Cancer Recruiting NCT01905046 Phase 3
20 Suction Drain Versus the Use of Adaptive Skin Sutures After Mastectomy ± Axillary Lymphadenectomy; a Prospective Randomised Study Recruiting NCT01509781 Phase 3
21 Oxybutynin Chloride in Managing Hot Flashes Recruiting NCT02961790 Phase 3
22 Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Recruiting NCT01272037 Phase 3
23 Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer Recruiting NCT02954874 Phase 3
24 Therapeutic Nipple Sparing Mastectomy. Recruiting NCT02311959 Phase 3
25 Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) Recruiting NCT03036488 Phase 3
26 Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Active, not recruiting NCT00769379 Phase 3
27 Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ Active, not recruiting NCT00072462 Phase 3
28 Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in Situ Active, not recruiting NCT00003857 Phase 3
29 RAPID: Randomized Trial of Accelerated Partial Breast Irradiation Active, not recruiting NCT00282035 Phase 3
30 APBI Versus EBRT Therapy After Breast Conserving Surgery for Low-risk Breast Cancer Active, not recruiting NCT00402519 Phase 3
31 Radiation Doses and Fractionation Schedules in Non-low Risk Ductal Carcinoma In Situ (DCIS) of the Breast Active, not recruiting NCT00470236 Phase 3
32 Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia Active, not recruiting NCT01357772 Phase 3
33 Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast Cancer Active, not recruiting NCT00004205 Phase 3
34 Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery Active, not recruiting NCT01349322 Phase 3
35 Randomized Controlled Trial of Neo-adjuvant Progesterone and Vitamin D3 in Women With Large Operable Breast Cancer and Locally Advanced Breast Cancer Active, not recruiting NCT01608451 Phase 3
36 Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation Active, not recruiting NCT00673335 Phase 3
37 Spect Analysis of Cardiac Perfusion Changes After Whole Breast/Chest Wall Radiation Therapy With Active Breathing Coordinator Active, not recruiting NCT00321048 Phase 3
38 Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer Active, not recruiting NCT00083174 Phase 3
39 Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer Active, not recruiting NCT00878709 Phase 3
40 A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE) Active, not recruiting NCT01772472 Phase 3
41 A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer Active, not recruiting NCT01358877 Phase 3
42 Study Comparing GW572016 And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer Active, not recruiting NCT00073528 Phase 3
43 Management of Low-risk DCIS Not yet recruiting NCT02492607 Phase 3
44 Risedronate in Improving Bone Mineral Density and Bone Health in Postmenopausal Women With Ductal Carcinoma In Situ Enrolled in Clinical Trial CRUK-IBIS-II-DCIS Withdrawn NCT00324714 Phase 3
45 Tamoxifen in Preventing Breast Cancer in Women at Increased Risk for Breast Cancer Unknown status NCT00096369 Phase 2
46 Effect of Omega 3 on Atrophic Vaginitis in Breast Cancer Survivors Unknown status NCT02150525 Phase 2
47 "Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer" Unknown status NCT01641406 Phase 2
48 Dose Optimization for Pulsed-dose-rate (PDR)/High-dose-rate (HDR) Brachytherapy Alone for Early Breast Cancer Unknown status NCT01175694 Phase 2
49 Whole Breast Irradiation With Intensity Modulated Radiotherapy and Simultaneously Integrated Boost for Early Stage Breast Cancer Patients Unknown status NCT01394575 Phase 2
50 Cisplatin-monotherapy in the Treatment of BRCA1 Positive Breast Cancer Patients in Poland Unknown status NCT01630226 Phase 2

Search NIH Clinical Center for Breast Carcinoma in Situ

Genetic Tests for Breast Carcinoma in Situ

Anatomical Context for Breast Carcinoma in Situ

MalaCards organs/tissues related to Breast Carcinoma in Situ:

39
Breast, Testes

Publications for Breast Carcinoma in Situ

Articles related to Breast Carcinoma in Situ:

(show all 44)
id Title Authors Year
1
Breast carcinoma in situ: An observational study of tumor subtype, treatment and outcomes. ( 27926499 )
2016
2
Mammographic extent of microcalcifications and oestrogen receptor expression affect preoperative breast carcinoma in situ size estimation. ( 27639877 )
2016
3
The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study. ( 26062614 )
2015
4
Usefulness and limitations of E-cadherin and I^-catenin in the classification of breast carcinomas in situ with mixed pattern. ( 23837653 )
2013
5
Mondor's disease in a patient previously treated for breast carcinoma in situ: a case report. ( 22595929 )
2012
6
Differences in breast carcinoma in situ between menopausal and premenopausal women. ( 21617240 )
2011
7
Pregnancy-related factors and the risk of breast carcinoma in situ and invasive breast cancer among postmenopausal women in the California Teachers Study cohort. ( 20565829 )
2010
8
Prevalence of BRCA1 and BRCA2 mutations in women with breast carcinoma In Situ and referred for genetic testing. ( 21149333 )
2010
9
Might the widespread use of statin drugs explain the increase in prevalence of breast carcinoma in situ? ( 19896281 )
2010
10
Prevalence of breast carcinoma in situ in the United States. ( 19706857 )
2009
11
The occurrence of invasive cancers following a diagnosis of breast carcinoma in situ. ( 18665169 )
2008
12
OSM, LIF, its receptors, and its relationship with the malignance in human breast carcinoma (in situ and in infiltrative). ( 18317962 )
2008
13
Risk factors for breast carcinoma in situ versus invasive breast cancer in a prospective study of pre- and post-menopausal women. ( 17063272 )
2007
14
An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ. ( 17244359 )
2007
15
Oral contraceptive use and risk of breast carcinoma in situ. ( 18006914 )
2007
16
Cigarette smoking and risk of breast carcinoma in situ. ( 17700252 )
2007
17
Quality of life for women diagnosed with breast carcinoma in situ. ( 17050872 )
2006
18
Molecular classification of breast carcinoma in situ. ( 17375183 )
2006
19
Oral contraceptive use and risk of breast carcinoma in situ (United States). ( 17006721 )
2006
20
Postmenopausal levels of sex hormones and risk of breast carcinoma in situ: results of a prospective study. ( 15540225 )
2005
21
Expression patterns of angiogenic and lymphangiogenic factors in ductal breast carcinoma in situ. ( 15841074 )
2005
22
Impact of reproductive factors and lactation on breast carcinoma in situ risk. ( 15054874 )
2004
23
Proliferative lesions of the breast: carcinoma in situ. ( 15022899 )
2003
24
Family history of breast and ovarian cancer and the risk of breast carcinoma in situ. ( 12611452 )
2003
25
Lifetime recreational exercise activity and risk of breast carcinoma in situ. ( 14601085 )
2003
26
Hypoxia promotes a dedifferentiated phenotype in ductal breast carcinoma in situ. ( 12670886 )
2003
27
The risk of a contralateral breast cancer among women diagnosed with ductal and lobular breast carcinoma in situ: data from the Connecticut Tumor Registry. ( 14659121 )
2003
28
Oral contraceptives and the risk of ductal breast carcinoma in situ. ( 14572155 )
2003
29
DNA content and cell number determination in microdissected samples of breast carcinoma in situ. ( 12118344 )
2002
30
Breast carcinoma in situ: risk factors and screening patterns. ( 11734598 )
2001
31
p53 mutations and expression in breast carcinoma in situ. ( 10623666 )
2000
32
Breast carcinoma in situ in a male. Report of a case diagnosed by nipple discharge cytology. ( 9622698 )
1998
33
Time trend of female breast carcinoma in situ by race and histology in Connecticut, USA. ( 9071907 )
1997
34
Biophenotypes of breast carcinoma in situ defined by image analysis of biological parameters. ( 8692711 )
1996
35
Biological heterogeneity of breast carcinoma in situ. ( 8651598 )
1996
36
Male breast carcinoma in situ. Report of a case diagnosed by nipple discharge cytology alone. ( 7654052 )
1995
37
Receptors for estrogen and progesterone in breast carcinoma in situ. ( 1295456 )
1992
38
Breast carcinoma in situ. ( 20169700 )
1992
39
Ten-year follow-up of breast carcinoma in situ in Connecticut. ( 1365682 )
1992
40
Breast carcinoma-in-situ: an emerging problem in Singapore. ( 1329232 )
1992
41
Breast carcinoma in situ in 167 women--incidence, mode of presentation, therapy and follow-up. ( 1657650 )
1991
42
Relationship between c-erbB-2 immunoreactivity and thymidine labelling index in breast carcinoma in situ. ( 1677296 )
1991
43
Breast carcinoma in situ. ( 2535929 )
1989
44
Breast carcinoma in situ. A retrospective review of 112 cases with a minimum 10 year follow-up. ( 2990246 )
1985

Variations for Breast Carcinoma in Situ

Expression for Breast Carcinoma in Situ

Search GEO for disease gene expression data for Breast Carcinoma in Situ.

Pathways for Breast Carcinoma in Situ

Pathways related to Breast Carcinoma in Situ according to GeneCards Suite gene sharing:

(show top 50) (show all 76)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.22 ERBB2 ESR1 FGF2 FGFR1 FLT4 IL6
2
Show member pathways
13.87 FGF2 FGFR1 FLT4 IL6 IL6ST KDR
3
Show member pathways
13.83 BRCA1 ERBB2 ESR1 FGF2 FGFR1 FLT4
4
Show member pathways
13.67 ERBB2 FGFR1 FLT4 IL6 IL6ST KDR
5
Show member pathways
13.62 BRCA1 BRCA2 ERBB2 ESR1 FGF2 FGFR1
6
Show member pathways
13.6 ERBB2 FGF2 FGFR1 FLT4 IL6 KDR
7
Show member pathways
13.54 ERBB2 FGF2 FGFR1 KDR KRT19 MET
8
Show member pathways
13.53 BRCA1 ERBB2 FGF2 FGFR1 FLT4 IL6
9
Show member pathways
13.42 ERBB2 FGF2 FGFR1 FLT4 IL6 KDR
10
Show member pathways
13.36 ERBB2 FGF2 FGFR1 FLT4 IL6 KDR
11
Show member pathways
13.35 ERBB2 FGF2 FGFR1 IL6 IL6ST LIF
12
Show member pathways
13.33 ERBB2 FGF2 FGFR1 FLT4 IL6 KDR
13
Show member pathways
13.26 ERBB2 ESR1 FGF2 FGFR1 FLT4 IL6
14
Show member pathways
13.1 FGF2 FGFR1 FLT4 IL6 KDR MET
15
Show member pathways
13.09 FGF2 FGFR1 FLT4 IL6 KDR MET
16
Show member pathways
12.94 ERBB2 FLT4 KDR MET VEGFA VEGFC
17
Show member pathways
12.83 ERBB2 ESR1 MET TP53 VEGFA
18
Show member pathways
12.77 ERBB2 FGF2 FGFR1 MET TP53
19
Show member pathways
12.77 FGF2 FGFR1 FLT4 KDR MET VEGFA
20
Show member pathways
12.73 FGF2 FGFR1 FLT4 IL6 KDR MET
21
Show member pathways
12.64 ERBB2 FGF2 IL6 MMP2 TP53
22
Show member pathways
12.57 ERBB2 FGFR1 FLT4 KDR MET TP53
23 12.55 BRCA1 ERBB2 MET TP53 VEGFA
24 12.55 BRCA2 ERBB2 FGF2 FGFR1 IL6 MET
25
Show member pathways
12.5 ERBB2 FGFR1 FLT4 KDR MET TP53
26
Show member pathways
12.44 BRCA1 ESR1 KDR VEGFA
27
Show member pathways
12.4 FLT4 KDR VEGFA VEGFC
28
Show member pathways
12.4 FGF2 FGFR1 FLT4 KDR MET VEGFA
29 12.39 BRCA1 FGF2 FGFR1 FLT4 IL6 KDR
30
Show member pathways
12.33 BRCA1 BRCA2 ERBB2 ESR1 FGF2 FGFR1
31
Show member pathways
12.29 FGF2 FGFR1 KDR VEGFA VEGFC
32 12.23 IL6 MMP2 TP53 VEGFA
33 12.22 BRCA1 BRCA2 ESR1 TP53 VEGFA
34
Show member pathways
12.22 ERBB2 FGFR1 FLT4 KDR MET TP53
35
Show member pathways
12.17 ERBB2 IL6 IL6ST MMP2
36
Show member pathways
12.15 BRCA2 ERBB2 TP53 VEGFA
37 12.14 KDR MMP2 TP53 VEGFA
38 12.14 FGF2 FGFR1 IL6ST LIF
39 12.11 LIF MET MMP2 TP53
40 12.06 ERBB2 FGF2 FGFR1 FLT4 KDR MET
41 11.99 FGF2 IL6 LIF MMP2 TP53 VEGFA
42 11.99 FGF2 IL6 KDR KRT19 LIF MET
43 11.96 IL6 MMP2 VEGFA VEGFC
44
Show member pathways
11.92 FLT4 KDR VEGFA VEGFC
45 11.92 ERBB2 ESR1 FGF2 FGFR1 KDR MET
46
Show member pathways
11.9 ERBB2 ESR1 VEGFA
47
Show member pathways
11.85 BRCA1 BRCA2 TP53
48 11.85 FGF2 FGFR1 FLT4 KDR MMP2 VEGFC
49
Show member pathways
11.84 FGFR1 FLT4 KDR
50 11.83 FGF2 FGFR1 VEGFA

GO Terms for Breast Carcinoma in Situ

Cellular components related to Breast Carcinoma in Situ according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.36 FGF2 FGFR1 FLT4 IL6 IL6ST KDR
2 interleukin-6 receptor complex GO:0005896 8.96 IL6 IL6ST

Biological processes related to Breast Carcinoma in Situ according to GeneCards Suite gene sharing:

(show top 50) (show all 54)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.98 FGF2 FLT4 IL6 KDR
2 protein autophosphorylation GO:0046777 9.97 ERBB2 FGFR1 FLT4 KDR
3 positive regulation of protein phosphorylation GO:0001934 9.96 ERBB2 FLT4 KDR VEGFA
4 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.93 ERBB2 FLT4 KDR MET
5 phosphatidylinositol phosphorylation GO:0046854 9.91 ERBB2 FGF2 FGFR1 MET
6 lung development GO:0030324 9.89 FGFR1 LIF VEGFA
7 wound healing GO:0042060 9.89 ERBB2 FGF2 IL6
8 regulation of phosphatidylinositol 3-kinase signaling GO:0014066 9.89 ERBB2 FGF2 FGFR1 MET
9 positive regulation of angiogenesis GO:0045766 9.89 BRCA1 FGF2 KDR VEGFA VEGFC
10 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.88 FLT4 KDR VEGFA VEGFC
11 phosphatidylinositol-mediated signaling GO:0048015 9.88 ERBB2 FGF2 FGFR1 MET TP53
12 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.87 IL6 LIF VEGFA
13 response to estrogen GO:0043627 9.86 BRCA1 ESR1 KRT19
14 positive regulation of epithelial cell proliferation GO:0050679 9.85 ERBB2 IL6 VEGFA VEGFC
15 positive regulation of cell division GO:0051781 9.84 FGF2 VEGFA VEGFC
16 positive regulation of endothelial cell migration GO:0010595 9.84 FLT4 KDR VEGFA
17 positive regulation of MAP kinase activity GO:0043406 9.84 ERBB2 FGF2 FGFR1 VEGFA
18 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.83 IL6 IL6ST LIF VEGFA
19 positive regulation of tyrosine phosphorylation of Stat3 protein GO:0042517 9.82 IL6 IL6ST LIF
20 lung alveolus development GO:0048286 9.81 FLT4 LIF PGR
21 regulation of angiogenesis GO:0045765 9.81 ERBB2 FGF2 IL6
22 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.8 IL6 LIF TP53 VEGFA VEGFC
23 positive regulation of vascular endothelial growth factor production GO:0010575 9.79 BRCA1 FLT4 IL6ST
24 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.78 FLT4 KDR VEGFA
25 positive regulation of blood vessel endothelial cell migration GO:0043536 9.77 FGF2 VEGFA VEGFC
26 positive regulation of MAPK cascade GO:0043410 9.77 FGFR1 FLT4 IL6 KDR LIF
27 cell migration involved in sprouting angiogenesis GO:0002042 9.75 FGF2 KDR VEGFA
28 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.74 BRCA1 BRCA2 TP53
29 positive chemotaxis GO:0050918 9.73 FGF2 MET VEGFA VEGFC
30 peptidyl-tyrosine phosphorylation GO:0018108 9.73 ERBB2 FGF2 FGFR1 FLT4 KDR MET
31 branching involved in salivary gland morphogenesis GO:0060445 9.71 FGFR1 IL6
32 positive regulation of positive chemotaxis GO:0050927 9.71 KDR VEGFA
33 negative regulation of hormone secretion GO:0046888 9.71 IL6 LIF
34 positive regulation of astrocyte differentiation GO:0048711 9.7 IL6ST LIF
35 positive regulation of tyrosine phosphorylation of Stat1 protein GO:0042511 9.7 IL6ST LIF
36 positive regulation of acute inflammatory response GO:0002675 9.7 IL6 IL6ST
37 interleukin-6-mediated signaling pathway GO:0070102 9.69 IL6 IL6ST
38 positive regulation of protein kinase C signaling GO:0090037 9.69 FLT4 VEGFA
39 positive regulation of phospholipase C activity GO:0010863 9.69 ESR1 FGF2 FGFR1
40 vascular endothelial growth factor signaling pathway GO:0038084 9.68 FLT4 KDR
41 positive regulation of mast cell chemotaxis GO:0060754 9.68 VEGFA VEGFC
42 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.67 KDR VEGFA
43 positive regulation of endothelial cell chemotaxis to fibroblast growth factor GO:2000546 9.65 FGF2 FGFR1
44 leukemia inhibitory factor signaling pathway GO:0048861 9.65 IL6ST LIF
45 positive regulation of endothelial cell proliferation GO:0001938 9.55 FGF2 FLT4 KDR VEGFA VEGFC
46 chordate embryonic development GO:0043009 9.5 BRCA1 BRCA2 FGFR1
47 angiogenesis GO:0001525 9.5 FGF2 FGFR1 FLT4 KDR MMP2 VEGFA
48 positive regulation of cell proliferation GO:0008284 9.28 FGF2 FGFR1 FLT4 IL6 IL6ST KDR
49 positive regulation of transcription, DNA-templated GO:0045893 10.12 BRCA1 BRCA2 ESR1 FGF2 IL6 TP53
50 positive regulation of transcription from RNA polymerase II promoter GO:0045944 10.11 BRCA1 ESR1 FGF2 IL6 LIF MET

Molecular functions related to Breast Carcinoma in Situ according to GeneCards Suite gene sharing:

(show all 15)
id Name GO ID Score Top Affiliating Genes
1 protein kinase activity GO:0004672 9.95 ERBB2 FGFR1 FLT4 KDR MET
2 cytokine activity GO:0005125 9.83 FGF2 IL6 LIF VEGFA
3 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.76 ERBB2 FGF2 FGFR1 MET
4 growth factor activity GO:0008083 9.72 FGF2 IL6 LIF VEGFA VEGFC
5 protein phosphatase binding GO:0019903 9.71 ERBB2 FLT4 MET TP53
6 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.67 ERBB2 FGF2 FGFR1 MET
7 chemoattractant activity GO:0042056 9.61 FGF2 VEGFA VEGFC
8 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.54 ERBB2 KDR
9 interleukin-6 receptor binding GO:0005138 9.51 IL6 IL6ST
10 vascular endothelial growth factor-activated receptor activity GO:0005021 9.49 FLT4 KDR
11 receptor-receptor interaction GO:0090722 9.48 FGF2 FGFR1
12 growth factor binding GO:0019838 9.46 ERBB2 FLT4 IL6ST KDR
13 protein tyrosine kinase activity GO:0004713 9.43 ERBB2 FGF2 FGFR1 FLT4 KDR MET
14 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.02 ERBB2 FGFR1 FLT4 KDR MET
15 protein binding GO:0005515 10.21 BRCA1 BRCA2 ERBB2 ESR1 FGF2 FGFR1

Sources for Breast Carcinoma in Situ

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....